Stay updated on Mocetinostat and Vinorelbine in Rhabdomyosarcoma Clinical Trial
Sign up to get notified when there's something new on the Mocetinostat and Vinorelbine in Rhabdomyosarcoma Clinical Trial page.

Latest updates to the Mocetinostat and Vinorelbine in Rhabdomyosarcoma Clinical Trial page
- ChecktodayNo Change Detected
- Check7 days agoChange DetectedThe NIH site-transition announcement banner is no longer displayed above the 403 Forbidden page.SummaryDifference1%

- Check14 days agoChange DetectedThe footer’s ClinicalTrials.gov revision label changed from v3.7.2 to v3.8.0.SummaryDifference0.2%

- Check21 days agoChange DetectedA notice announces NIH transition updates and says federal agencies are using “Super Intelligence” in place of “Artificial Intelligence” during the transition.SummaryDifference1%

- Check28 days agoChange DetectedThe footer’s ClinicalTrials.gov revision label changes from v3.7.1 to v3.7.2; the study page still displays a 403 Forbidden error.SummaryDifference0.2%

- Check35 days agoChange DetectedThe site revision identifier in the footer changes from v3.7.0 to v3.7.1; the page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check56 days agoChange DetectedVersion update to Revision: v3.7.0 is shown, and a large block of terms and fields—such as regulatory status, the study drugs, disease/MeSH terms, and key eligibility/outcome descriptors—were removed from the page. This change alters how the study is described and indexed on ClinicalTrials.gov.SummaryDifference19%

Stay in the know with updates to Mocetinostat and Vinorelbine in Rhabdomyosarcoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Mocetinostat and Vinorelbine in Rhabdomyosarcoma Clinical Trial page.